Vera Therapeutics reports preliminary cash of $114.7M as of Dec 31, 2022

Vera Therapeutics, Inc.

Preliminary unaudited cash, cash equivalents and marketable securities total approximately $114.7 million at Dec 31, 2022.
Quarter-end financial close for Q4 2022 is not yet complete; figure is subject to change upon finalization.
No additional financial results, revenue, or earnings data were provided in this filing.
The cash balance excludes any subsequent financing or operating activities through the filing date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.